NCT04614584View on ClinicalTrials.gov

Mirtazapine and Methamphetamine Drug-drug Interaction Study

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Methamphetamine Use DisorderDrug InteractionCardiovascular Abnormalities
Interventions
DRUG

Mirtazapine

Mirtazapine 30 mg PO daily x 4 days

DRUG

Methamphetamine

Methamphetamine 30 mg IV once

Trial Locations (3)

90095

UCLA Medical Center, Los Angeles

94102

San Francisco Department of Public Health, San Francisco

Substance Use Research Unit, San Francisco

All Listed Sponsors
collaborator

University of California, Los Angeles

OTHER

lead

San Francisco Department of Public Health

OTHER_GOV